Novel and Emerging Biomarkers in the Diagnosis and Management of Kidney Disease in Cirrhosis.

Authors

Elizabeth Reznik, Deirdre Reidy, Xiaohan Ying, Emily Schonfeld, Arun Jesudian

Published in

Journal of gastrointestinal and liver diseases : JGLD. Volume 35. Issue 2. Pages 263-275. Jun 27, 2026. Epub Jun 27, 2026.

Abstract

Acute kidney injury (AKI) and chronic kidney disease (CKD) are common conditions among patients with cirrhosis whose development is associated with increased morbidity and mortality. Recurrent episodes of AKI within this population can ultimately lead to CKD, while patients with underlying CKD are in turn more likely to experience AKI. Determining the etiology of kidney dysfunction in the setting of cirrhosis is often challenging given the considerable limitations of currently available diagnostic tools. Ongoing research into the role of novel serum and urine biomarkers may allow for more timely diagnosis and treatment of kidney injury among patients with cirrhosis. This review provides an overview of kidney dysfunction in cirrhosis with a focus on the role of these emerging biomarkers for diagnosis of AKI and CKD.

PMID:
42365654
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.